22 March, 2022

Hyris and its network want to make pragmatic impact Helping Ukrainian Families

Hyris is actively following the humanitarian crisis caused by Russian invasion of Ukraine started on February 24th. We have colleagues, friends and business partners in Ukraine. Since the beginning, we tried to actively help our colleagues and friends’ families to reach a safe place outside of Kiev. And, in case possible, outside of Ukraine.

Together with our network, we also wanted to further help as many women, children, and elder people as possible. Our initial priority is for them to find a stable solution for the next period. Therefore, as first step of our commitment, we are managing the transfer from the Ukranian border to Liepajia (Latvia), where we will manage accommodations and housing in a country where they can easily communicate, even if not English speaking. For each family we will pay for the housing for the next six months, also providing emergency relief items including food, medicines, clothes.

The first families already got to Liepaja. We need your contribution to help more families and make greater impact.

Our second priority is related to the diabetes emergency in Ukraine, for which we want to contribute supplying insulin, as one of the most needed item right now. We are evaluating different solution and choosing the most impactful one. We will give more details soon.

Donate here and get information about our initiative.

  • Hyris and Singlabs signed a distributorship agreement for Singapore

  • Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

  • Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

  • Hyris to participate in SEI 2022 in Leon, hosted by the Sociedad Española de Immunologia

  • Hyris' new T-cell Test is finally available to EU Countries to easily map patients' cellular immunity to SARS-CoV-2

  • Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich

  • A new T-cell activation assay based on Hyris technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity.

  • Hyris and its network want to make pragmatic impact Helping Ukrainian Families

  • Hyris presented its new, disruptive T-Cell test at the international conference "A-Wish", fully embracing the Immunology sector to better fight COVID-19 and beyond.

  • Hyris releases its new Demo to better support all prospect users of its portable and reliable molecular test for diagnosing SARS-CoV-2 into human subjects.

Subscribe our newsletter

For periodical updates about Hyris solutions.

Connect with us

Contact Us